Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI(2022)

引用 4|浏览9
暂无评分
摘要
Our second case is a 49-year-old female patient, two days after receiving BNT162b2 mRNA COVID-19 vaccine, petechiae was started in arms and then in lower extremities. The complaints of weakness and fatigue continued to increase within days. The patient, who was admitted to the hospital ten days later with these complaints, was found to have bi-cytopenia. Bone marrow aspiration and biopsy reported that 20-30% stained with cd19 diffuse positive Terminal deoxynucleotidyl transferase (TdT) in blastic cells. HyperCVAD chemotherapy was started with the diagnosis of b-acute lymphoOur third case is a 57-year-old male patient, difficulty in swallowing, and oral ulceration after vaccination of BNT162b2 mRNA COVID-19 vac
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要